Acurx Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.9 million compared to USD 2.67 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.26 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | -1.52% | -10.19% | -49.35% |
May. 02 | Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference | CI |
Apr. 04 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.35% | 31.17M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- ACXP Stock
- News Acurx Pharmaceuticals, Inc.
- Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023